Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
Urpo Kiiskinen,1 Stephan Matthaei,2 Matthew Reaney,3 Chantal Mathieu,4 Claes-Göran Östenson,5 Thure Krarup,6 Michael Theodorakis,7,* Jacek Kiljanski,8 Carole Salaun-Martin,9 Hélène Sapin,9 Bruno Guerci10 1Eli Lilly, Helsinki, Finland; 2Quakenbrück Diabetes Center, Quakenbrück, Germany; 3Eli Lilly, W...
Saved in:
Main Authors: | Kiiskinen U (Author), Matthaei S (Author), Reaney M (Author), Mathieu C (Author), Östenson C-G (Author), Krarup T (Author), Theodorakis M (Author), Kiljański J (Author), Salaun-Martin C (Author), Sapin H (Author), Guerci B (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
by: McDonell AL, et al.
Published: (2015) -
Bidding adieu
by: Shyam Verma
Published: (2015) -
It is time now to bid adieu!
by: Sandipan Dhar
Published: (2011) -
Long-acting preparations of exenatide
by: Cai Y, et al.
Published: (2013) -
BidSi6 and BidEL isoforms as a potential marker for predicting colorectal adenomatous polyps
by: Flora Forouzesh, et al.
Published: (2022)